Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal
Sarepta spent much of last year marching forward with its candidate SRP-9001, a gene therapy treatment for the rare but fatal Duchenne muscular dystrophy, eventually filing a BLA for an accelerated approval, with a May 29 PDUFA date and a likely adcomm on the way too.
The Cambridge, MA-based biotech on Thursday signed a commercial supply agreement with the New Jersey-based CDMO Catalent to manufacture SRP-9001 and to support other gene therapy candidates in Sarepta’s pipeline for another rare, genetic disease related to muscle deterioration, known as limb-girdle muscular dystrophy (LGMD). Financial details of the deal were not disclosed and Endpoints News did not hear back from Catalent by press time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.